Singapore, Nov. 5 -- Simcere Pharmaceutical Group and Aeromics, Inc. have announced collaboration and exclusive license agreement for AER-271, a clinical-stage anti-edema therapy, being developed for the treatment of stroke and other indications, in Greater China (mainland China, Hong Kong, Macau and Taiwan). According to the agreement, Simcere will be responsible for the clinical development and commercialization of AER-271 in Greater China.

Thomas Zindrick, Aeromics' Executive Vice Chairman said, "We are delighted to be working with Simcere to develop AER-271 in China. Simcere's leading position in the Greater China stroke market, their strengths in manufacturing and the collaborative nature of their team made for an ideal partner for ...